AOL Money & Finance

Analyst initiations: Cougar Biotech, Penford, AtriaCure

More

MOST NOTEWORTHY: Cougar Biotech, Penford and AtriaCure were today's noteworthy initiations:
  • Oppenheimer believes Cougar Biotech's (NASDAQ: CGRB) lead compound abiraterone is well positioned to address two underserved lines of therapy in prostate cancer with highly unmet medical needs. The firm assumed coverage of Cougar with a Buy rating and $43 target.
  • Jefferies believes Penford's (NASDAQ: PENX) initiatives to improve product mix and increase returns on capital should lift the company's valuation multiples, starting shares with a Buy rating and $33 target.
  • AtriaCure (NASDAQ: ATRC) was initiated with an Outperform rating and $17 target at Barrington, as they have confidence the company's minimally invasive approach will be the standard of care procedure for the less invasive surgical management of atrial fibrillation.
OTHER INITIATIONS:
Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 25, 2009: 11:55 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines